Loading…
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-112M | $-106M | $-85M | -77.6% | - | 22.2% |
| 2024 | $0M | $-95M | $-87M | $-81M | -57.2% | - | 13.8% |
| 2023 | $0M | $-84M | $-76M | $-65M | -33.8% | - | 30.0% |
| 2022 | $0M | $-59M | $-59M | $-56M | -30.0% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 0 | 0 | 0 | 0 |
| Operating Revenue | - | 0 | 0 | 0 | 0 |
| Operating Expense | - | 60.30 | 84.99 | 96.12 | 112.79 |
| Research And Development | - | 42.24 | 65.23 | 73.30 | 90.30 |
| Selling General And Administration | - | 18.06 | 19.76 | 22.81 | 22.49 |
| Total Expenses | - | 60.30 | 84.99 | 96.12 | 112.79 |
| Operating Income | - | -60.30 | -84.99 | -96.12 | -112.79 |
| Total Operating Income As Reported | - | -60.30 | -84.99 | -96.12 | -112.79 |
| EBITDA | - | -59.12 | -83.70 | -94.89 | -111.66 |
| Normalized EBITDA | - | -58.80 | -83.90 | -94.89 | -111.66 |
| EBIT | - | -60.30 | -84.99 | -96.12 | -112.79 |
| Interest Income | - | 1.86 | 8.59 | 9.43 | 6.63 |
| Net Interest Income | - | 1.86 | 8.59 | 9.43 | 6.63 |
| Other Non Operating Income Expenses | - | -0.01 | -0.08 | -0.12 | 0.08 |
| Other Income Expense | - | -0.33 | 0.13 | -0.12 | 0.08 |
| Interest Income Non Operating | - | 1.86 | 8.59 | 9.43 | 6.63 |
| Net Non Operating Interest Income Expense | - | 1.86 | 8.59 | 9.43 | 6.63 |
| Pretax Income | - | -58.76 | -76.27 | -86.81 | -106.08 |
| Tax Provision | - | 0 | 0.14 | 0.11 | 0.11 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -58.76 | -76.41 | -86.92 | -106.19 |
| Net Income From Continuing And Discontinued Operation | - | -58.76 | -76.41 | -86.92 | -106.19 |
| Net Income From Continuing Operation Net Minority Interest | - | -58.76 | -76.41 | -86.92 | -106.19 |
| Net Income | - | -58.76 | -76.41 | -86.92 | -106.19 |
| Net Income Common Stockholders | - | -58.76 | -76.41 | -86.92 | -106.19 |
| Net Income Including Noncontrolling Interests | - | -58.76 | -76.41 | -86.92 | -106.19 |
| Normalized Income | - | -58.44 | -76.62 | -86.92 | -106.19 |
| Diluted NI Availto Com Stockholders | - | -58.76 | -76.41 | -86.92 | -106.19 |
| Basic Average Shares | - | 29.94 | 39.62 | 49.65 | 60.34 |
| Diluted Average Shares | - | 29.94 | 39.62 | 49.65 | 60.34 |
| Reconciled Depreciation | - | 1.18 | 1.30 | 1.22 | 1.13 |
| Total Unusual Items | 0 | -0.32 | 0.21 | 0 | - |
| Total Unusual Items Excluding Goodwill | 0 | -0.32 | 0.21 | 0 | - |
| Preferred Stock Dividends | 10.94 | - | - | - | - |
| Special Income Charges | 0 | -0.32 | 0.21 | 0 | - |
| Gain On Sale Of Security | -0.01 | -0.01 | - | - | - |
| General And Administrative Expense | - | 18.06 | 19.76 | 22.81 | 22.49 |
| Other Gand A | - | 18.06 | 19.76 | 22.81 | 22.49 |
| Gain On Sale Of Ppe | 0 | -0.32 | 0.21 | 0 | - |
| Total Other Finance Cost | -0.01 | - | - | - | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Aura Biosciences, Inc.this co. | AURA | $703M | -6.62 | 5.13 | -77.6% | -5.92 |
| Bright Minds Biosciences Inc. | DRUG | $731M | -59.77 | 8.91 | -14.9% | -46.77 |
| Solid Biosciences Inc. | SLDB | $713M | -4.09 | 3.96 | -96.8% | -3.80 |
| CBLL | CBLL | $711M | -13.32 | 4.58 | -34.4% | -13.81 |
| Enhabit, Inc. | EHAB | $707M | -153.68 |
| - |
| - |
| - |
| - |
| 1.32 |
| -0.9% |
| 20.09 |
| Allogene Therapeutics, Inc. | ALLO | $704M | -3.69 | 2.41 | -65.3% | -4.15 |
| Candel Therapeutics, Inc. | CADL | $679M | -17.79 | 13.08 | -73.5% | -17.28 |
| Design Therapeutics, Inc. | DSGN | $672M | -9.63 | 3.16 | -32.8% | -8.33 |
| CorMedix Inc. | CRMD | $670M | 4.13 | 1.65 | 40.0% | 4.01 |
| Peer Median | - | -11.47 | 3.56 | -33.6% | -6.24 | |